reviews glp-1 Scientist Bioma GLP1 Booster New research is taking a

10.1016/S0140-6736(19)31271-1 Summary Keywords colorectal cancer, gastrointestinal cancer, GLP-1 receptor agonists, liver cancer, meta-analysis, obesity, oncological safety, pancreatic cancer Citation Wali AF, Rangraze I, Khan S, Mufti UB, El-Tanani M and Rizzo M (2026) Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies

4), which did not withstand the adjustment for weight loss (Supplementary Table 2)

GLP1R: agonists (Ozempic, Wegovy): Hold oral dose the morning of surgery

doi: 10.3390/nu12020476 [DOI] [PMC free article] [PubMed] [Google Scholar] 192

Strategies for maintaining results after stopping Some people successfully maintain their results after discontinuing GLP-1 therapy